These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 36060006)

  • 1. Anti-tumour necrosis factor-alpha agent therapy, compared with conventional therapy, reduces the relapse of uveitis in patients with behçet's disease: A systematic review of controlled trials.
    Zhou X; Shi X; Ren Y; Yan T; Ye Q
    Front Pharmacol; 2022; 13():912906. PubMed ID: 36060006
    [No Abstract]   [Full Text] [Related]  

  • 2. Anti-TNF-α agents for refractory intestinal Behçet's disease: case series and meta-analysis.
    Zhan S; Liu C; Li N; Li T; Tian Z; Zhao M; Wu D; Chen M; Zeng Z; Zhuang X
    Therap Adv Gastroenterol; 2022; 15():17562848221116666. PubMed ID: 36082178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Anti-Tumor Necrosis Factor-Alpha Agents for Patients with Intestinal Behcet's Disease: A Systematic Review and Meta-Analysis.
    Zhang Q; Ma C; Dong R; Xiang W; Li M; Ma Z; Yang Q
    Yonsei Med J; 2022 Feb; 63(2):148-157. PubMed ID: 35083900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of Th17 differentiation by anti-TNF-alpha therapy in uveitis patients with Behçet's disease.
    Sugita S; Kawazoe Y; Imai A; Yamada Y; Horie S; Mochizuki M
    Arthritis Res Ther; 2012 May; 14(3):R99. PubMed ID: 22546542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-tumour necrosis factor biological therapies for the treatment of uveitic macular oedema (UMO) for non-infectious uveitis.
    Barry RJ; Tallouzi MO; Bucknall N; Mathers JM; Murray PI; Calvert MJ; Moore DJ; Denniston AK
    Cochrane Database Syst Rev; 2018 Dec; 12(12):CD012577. PubMed ID: 30562409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-TNF-α therapy in patients with refractory uveitis due to Behçet's disease: a 1-year follow-up study of 124 patients.
    Calvo-Río V; Blanco R; Beltrán E; Sánchez-Bursón J; Mesquida M; Adán A; Hernandez MV; Hernandez Garfella M; Valls Pascual E; Martínez-Costa L; Sellas-Fernández A; Cordero Coma M; Díaz-Llopis M; Gallego R; Salom D; García Serrano JL; Ortego N; Herreras JM; Fonollosa A; García-Aparicio AM; Maíz O; Blanco A; Torre I; Fernández-Espartero C; Jovani V; Peiteado-Lopez D; Pato E; Cruz J; Fernández-Cid C; Aurrecoechea E; García M; Caracuel MA; Montilla C; Atanes A; Hernandez FF; Insua S; González-Suárez S; Sánchez-Andrade A; Gamero F; Linares L; Romero-Bueno F; García AJ; Almodovar R; Minguez E; Carrasco Cubero C; Olive A; Vázquez J; Ruiz Moreno O; Jiménez-Zorzo F; Manero J; Muñoz Fernández S; Rueda-Gotor J; González-Gay MA
    Rheumatology (Oxford); 2014 Dec; 53(12):2223-31. PubMed ID: 24996907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Efficacy of Medium- to Long-term Anti-TNF-α Antibody-based Maintenance Therapy in Behçet's Disease Patients with Intestinal Lesions.
    Kambayashi H; Omori T; Saito S; Murasugi S; Kashiwagi H; Ito A; Yonezawa M; Nakamura S; Tokushige K
    Intern Med; 2020; 59(19):2343-2351. PubMed ID: 32999263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy and safety of anti-tumor necrosis factor agents in the treatment of intestinal Behcet's disease, a systematic review and meta-analysis.
    Zhang M; Liu J; Liu T; Han W; Bai X; Ruan G; Lv H; Shu H; Li Y; Li J; Tan B; Zheng W; Xu H; Zheng W; Yang H; Qian J
    J Gastroenterol Hepatol; 2022 Apr; 37(4):608-619. PubMed ID: 34894004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk Factors for Surgery in Patients with Intestinal Behçet's Disease During Anti-Tumor Necrosis Factor-Alpha Therapy.
    Han SJ; Kang EA; Park J; Park SJ; Park JJ; Kim TI; Kim WH; Cheon JH
    Yonsei Med J; 2023 Feb; 64(2):111-116. PubMed ID: 36719018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical manifestations and anti-TNF alpha therapy of juvenile Behçet's disease in Taiwan.
    Hu YC; Yang YH; Lin YT; Wang LC; Yu HH; Lee JH; Chiang BL
    BMC Pediatr; 2019 Jul; 19(1):232. PubMed ID: 31296171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current and future treatments for Behçet's uveitis: road to remission.
    Mesquida M; Molins B; Llorenç V; Hernández MV; Espinosa G; Dick AD; Adán A
    Int Ophthalmol; 2014 Apr; 34(2):365-81. PubMed ID: 23729309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switching of anti-TNF-α agents in Behçet's disease.
    Furuta S; Chow YW; Chaudhry AN; Jayne D
    Clin Exp Rheumatol; 2012; 30(3 Suppl 72):S62-8. PubMed ID: 23010387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biologic therapy for Behçet's uveitis: a systematic review.
    Uke P; Gorodkin R; Beare N
    Br J Ophthalmol; 2020 Aug; 104(8):1045-1051. PubMed ID: 31676596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor necrosis factor (TNF)-308, -1031, and angiotensin-converting enzyme (ACE) DD/II polymorphisms' role in Behcet's disease with and without uveitis: a meta-analysis.
    Jabbarpoor Bonyadi MH; Yaseri M; Soheilian M
    Ophthalmic Genet; 2020 Jun; 41(3):235-239. PubMed ID: 32323594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of intravitreal anti-tumour necrosis factor drugs in adults with non-infectious uveitis - a systematic review.
    Leal I; Rodrigues FB; Sousa DC; Romão VC; Duarte GS; Carreño E; Dick AD; Marques-Neves C; Costa J; Fonseca JE
    Acta Ophthalmol; 2018 Sep; 96(6):e665-e675. PubMed ID: 29577629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of anti-TNF alpha in severe and/or refractory Behçet's disease: Multicenter study of 124 patients.
    Vallet H; Riviere S; Sanna A; Deroux A; Moulis G; Addimanda O; Salvarani C; Lambert M; Bielefeld P; Seve P; Sibilia J; Pasquali J; Fraison J; Marie I; Perard L; Bouillet L; Cohen F; Sene D; Schoindre Y; Lidove O; Le Hoang P; Hachulla E; Fain O; Mariette X; Papo T; Wechsler B; Bodaghi B; Rigon MR; Cacoub P; Saadoun D;
    J Autoimmun; 2015 Aug; 62():67-74. PubMed ID: 26162757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The real-world use of different anti-tumor necrosis factor agents in a Northern European population of patients with Behçet's disease.
    Adeeb F; Ng WL; Khan MU; Devlin J; Stack AG; Fraser AD
    Eur J Rheumatol; 2017 Dec; 4(4):254-259. PubMed ID: 29308279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brief Report: Drug-Free Long-Term Remission in Severe Behçet's Disease Following Withdrawal of Successful Anti-Tumor Necrosis Factor Treatment.
    Sfikakis PP; Arida A; Panopoulos S; Fragiadaki K; Pentazos G; Laskari K; Tektonidou M; Markomichelakis N
    Arthritis Rheumatol; 2017 Dec; 69(12):2380-2385. PubMed ID: 28834393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of biologic agents in the treatment of ocular manifestations of Behcet's disease.
    Benitah NR; Sobrin L; Papaliodis GN
    Semin Ophthalmol; 2011; 26(4-5):295-303. PubMed ID: 21958178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A young girl with refractory intestinal Behçet's disease: a case report and review of literatures on pediatric cases who received an anti-tumor necrosis factor agent.
    Watanabe S; Aizawa-Yashiro T; Tsuruga K; Kinjo M; Ito E; Tanaka H
    Rheumatol Int; 2013 Dec; 33(12):3105-8. PubMed ID: 23266507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.